argenx SE (NASDAQ:ARGX) Stock Position Lifted by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. increased its position in argenx SE (NASDAQ:ARGX) by 3.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,524 shares of the company’s stock after acquiring an additional 440 shares during the quarter. argenx comprises approximately 1.2% of EFG Asset Management North America Corp.’s holdings, making the stock its 10th biggest position. EFG Asset Management North America Corp.’s holdings in argenx were worth $8,942,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Victory Capital Management Inc. lifted its position in shares of argenx by 69.8% in the third quarter. Victory Capital Management Inc. now owns 1,562 shares of the company’s stock valued at $847,000 after acquiring an additional 642 shares in the last quarter. Advisors Asset Management Inc. lifted its holdings in argenx by 15.3% in the 3rd quarter. Advisors Asset Management Inc. now owns 927 shares of the company’s stock worth $503,000 after purchasing an additional 123 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in argenx by 28.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,459 shares of the company’s stock worth $1,875,000 after purchasing an additional 768 shares in the last quarter. Raymond James Trust N.A. boosted its stake in argenx by 6.0% in the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock worth $268,000 after purchasing an additional 28 shares during the period. Finally, Cerity Partners LLC grew its holdings in argenx by 20.4% during the 3rd quarter. Cerity Partners LLC now owns 3,273 shares of the company’s stock valued at $1,774,000 after buying an additional 555 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Stock Down 1.1 %

ARGX opened at $607.95 on Tuesday. The business has a fifty day moving average of $633.44 and a 200 day moving average of $600.67. The stock has a market cap of $36.94 billion, a P/E ratio of -690.85 and a beta of 0.59. argenx SE has a 52-week low of $352.77 and a 52-week high of $678.21.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Equities analysts anticipate that argenx SE will post 3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company upped their target price on shares of argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Wedbush restated an “outperform” rating and set a $655.00 price objective on shares of argenx in a research report on Tuesday, December 3rd. Sanford C. Bernstein upgraded argenx from a “market perform” rating to an “outperform” rating in a research report on Monday, March 17th. Truist Financial restated a “buy” rating and set a $700.00 price target (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, Piper Sandler upped their price objective on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, argenx has a consensus rating of “Moderate Buy” and a consensus price target of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.